Vistagen Executives Load Up on Zero‑Price Options, Betting Big on Future Growth amid Current Low Valuation
Insider option grants at Vistagen Therapeutics signal executives’ confidence in the stock’s future value, hinting at potential upside amid clinical milestones.
3 minutes to read